Published in Vaccine Weekly, November 15th, 2006
Results from the studies suggest that the company's patented vaccine adjuvant known as Vaxfectin has the potential to be used as a dose-sparing agent with conventional flu vaccines against seasonal or pandemic flu strains. The company is developing a Vaxfectin-formulated DNA vaccine designed to protect against emerging strains of flu virus that have the potential to cause a pandemic. Larry R. Smith, PhD, the company's VP of Vaccine...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.